ASP0113 + Placebo
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Conditions
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Trial Timeline
Nov 20, 2013 → Nov 5, 2020
NCT ID
NCT01974206About ASP0113 + Placebo
ASP0113 + Placebo is a phase 2 stage product being developed by Astellas Pharma for Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT01974206. Target conditions include Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02103426 | Phase 1 | Completed |
| NCT01974206 | Phase 2 | Completed |
| NCT01877655 | Phase 3 | Completed |
Competing Products
20 competing products in Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients